The frequency of human papillomavirus findings in normal oral mucosa of healthy people by PCR

Keywords: mouth, papillomavirus infections, mouth mucosa.

Summary

The human papillomavirus (HPV) is a DNA virus, which belongs to papillomaviridae family, being of low and high risk, which infect the skin and mucous membranes and can induce benign and malign tumor formation. In the oral mucosa they have been associated with oral papilloma, focal epithelial hyperplasia, leukoplakia and oral neoplasia. **Aim:** to study the frequency of HPV finding in oral mucosa of normal people. **Materials and methods:** Prospective study, cross-sectional cohort. One hundred volunteers, young adults, healthy, aged between 20 and 31 years, university students with no history, no complains, without oral or oropharyngeal lesions. They were submitted to a questionnaire with questions regarding HPV infection epidemiology. The samples were harvested by brushing and analyzed by PCR. **Results:** The results were negative for HPV in all samples. **Conclusion:** It seems we had high social and economical class individuals, with nutrition rich in carotenoyds and vitamin C, low smoking and alcohol consumption and heterosexual habits with predominant monogamy and regular use of condoms.
INTRODUCTION

Skin and mucosa are the preferential sites infected by the human papillomavirus. HPV is frequently associated with benign and malignant neoplasms in the oral cavity, the most commonly of which being squamous cell carcinoma. The presence of HPV in the epithelium of normal oral mucosa, as reported in the literature, does not allow for accurate inferences regarding the virus' role on carcinogenesis, as to whether it is the main etiologic agent, merely a secondary force, or simply another inhabitant of the oral epithelium. In spite of the improvements introduced to oral mucosa HPV detection techniques, the virus direct involvement in the appearance of oral carcinomas is yet to be definitively proven. However, considering the HPV prevalence rates seen in lesions associated with the virus, its participation in carcinogenesis cannot be ruled out.

The human papillomavirus (HPV) belongs to the papillomaviridiae genus, papovaviridiae family, and has a double circular DNA strand with approximately 8,000 base pairs. This is a small non-enveloped virus, and its genome has its genes coded. Its capsid is icosahedral with a diameter ranging between 50nm and 60nm; the virus is not coated by a lipid envelope; it has 72 capsomeres and species-specific antigenic determiners in its outer surface and internally. This virus has a double DNA strand divided into early (E) and late (L) proteins, and regulating regions. The early region (E1-E8) codes genes for viral replication and host cell transformation. Proteins E6 and E7 are coded for oncogenic HPV types and have been shown to have a role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressing genes p53 and pRB. The role in negatively affecting the cell cycle by binding and deactivating tumor suppressin...
In terms of carcinogenesis, in situ hybridization was performed only to find HPV types 16 and 18 in oral cavity squamous cell carcinomas. The authors of a literature review on oral carcinogenesis found evidences that HPV types 16 and 18 are associated with early proteins that bind, sequester, and degrade tumor suppressing genes, with E6 acting on p53 and E7 similarly upon pRB1. They also observed that vDNA was integrated into tumor cells after division, indicating their participation in oncogenesis.

Authors looking at changes in eating habits indicated that regular intake of papaya, a fruit rich in carotenoids (lutein, zeaxanthin, and β-cryptoxanthin), and citric fruits (vitamin C) led to a reduction on the persistence of infection by HPV; evidences also indicate that increased levels of folic acid reduce the risk of infection for high-risk HPV strains.

According to the literature, prevalence rates of HPV in normal oral mucosae vary substantially. Our survey found values ranging from 0% to 100%[19,25-36, as seen on Table 1.

**OBJECTIVE**

This paper aims to enhance the knowledge on HPV epidemiology and prevalence rates in healthy individuals, so that future studies can determine which protection factors are present in these individuals, which mechanisms are in effect and how the virus participates in the genesis of tumors, so prophylactic and therapeutic measures are developed for the benefit of larger populations.

**MATERIALS AND METHOD**

This prospective cross-sectional survey was conducted between May 17, 2006 and April 11, 2007. One-hundred individuals with ages ranging between 20 and 31 years volunteered to participate in this study. Only individuals without previous history, complaints or present macroscopic oral cavity and oropharyngeal lesions were enrolled. All individuals answered a standard unidentified questionnaire numbered based on the collected samples. Epidemiologic factors connected to the transmission and persistence of HPV infection were addressed, such as gender, ethnicity, smoking, alcoholism, use of illicit drugs, sexual habits, number of sex partners, use of condoms, and eating habits specifically related to foods rich in vitamin C (citric fruit) and carotenoids (papaya). After carefully examining the individuals oral cavity and oropharynx using a photophore, samples were collected from the oral mucosa and the mastication sites using an Endobrush® brush. Samples were kept in refrigerated sterilized sealed numbered packages and sent to the Genic Expression Laboratory at the Carlos Chagas Filho Biophysics Institute to be analyzed through PCR (polymerase chain reaction). PCR was done using primers GP5+/GP6+ and MY09/

MY11 added to the DNA samples along with enzyme Taq polymerase, into the reaction compound containing all other components required for DNA synthesis. Then the reaction compound was placed on a thermocycler and submitted to repeated amplification cycles at different temperatures following the reaction phases: denaturation at 94°C, hybridization at 60°C, and synthesis at 72°C. The final product was amplified and analyzed through polyacrylamide gel electrophoresis. All reactions included a negative control (containing all components except for the DNA) and a positive control (in which a known standard gene was amplified).

This study was approved by the Research Ethics Committee at the Clementino Braga Filho University Hospital and registered before the Scientific Research Committee under the following permits: CEP:090/06 and CIC:062/06.

**RESULTS**

Questionnaire results - sample characterization:

Forty of the 100 individuals enrolled in our study were males and 60 were females; 86 claimed to be Caucasian, nine were brown and five were black; ages ranged between 20 and 31 years with a mean value of 22.65 years. In terms of tobacco consumption, 97/100 were non-smokers and 3/100 were smokers. Alcohol drinking was described in the following manner: 31/100 claimed not to have any alcohol; 56/100 have alcohol once a week; 3/100 have alcohol twice a week; 6/100 have it three times a week; 4/100 did not respond. Sex habits, as reported: 100/100 claimed to be heterosexuals; 85/100 have only one sex partner; 13/100 have more than one partner; 69/100 have oral sex; 22/100 do not have sex; 9/100 did not respond; 46/100 always wear condoms; 26/100 use condoms sometimes; 20/100 never wear condoms; 8 did not respond. Consumption of citric foods (vitamin C): 47/100 have them once a week; 26/100 have citric foods twice a week; 15/100 three times a week; 2/100 did not respond. Papaya consumption (carotenoids): 29/100 have them once a week; 15/100 have alcohol twice a week; 6/100 have it three times a week; 4/100 did not respond. Papaya consumption (carotenoids): 29/100 have them once a week; 26/100 have citric foods twice a week; 15/100 three times a week; 2/100 did not respond.

PCR results:

The questionnaire results on sample characterization can be seen on Table 2. PCR results were negative for all individuals involved.

**DISCUSSION**

Social-economic factors: anogenital infections by HPV appear to be directly connected to social and economic variables. Authors have reported that virgin adolescents usually do not have detectable levels of anal or genital HPV, while those sexually active from earlier ages and individuals engaged in prostitution are more prone
to having sexually transmitted diseases, HPV infection included. Low levels of HPV infection seem to be related to higher social and economic standards observed in the European population. In our sample, college students with average socio-economic status had negative PCR test results.

Eating habits: regular consumption of carotenoids (lutein, zeaxanthin, and β-cryptoxanthin) and vitamin C suggested reduced persistence of HPV infection and evidences indicate that increased levels of folic acid are inversely related to high-risk HPV infection. In our sample, consumption of nutrients (vitamin C and carotenoids) appeared at a significant rate, as 88% (88/100) claimed to have citric foods (sources of vitamin C) between once and three times a week and 39% (39/100) stated they have papaya (source of carotenoids) between once and three times a week. These factors might have contributed to reduced prevalence rates of HPV in our sample.

Sex habits: all subjects in our sample claimed to be heterosexuals (100%, 100/100). Considering that having multiple partners is a factor more frequently found among homosexuals, one may assume that heterosexuality has contributed to the reduction on the virus prevalence rates in our sample; however, no specific studies on HPV prevalence rates among homosexuals were found. In our sample individuals were mostly monogamists, as 6% (6/100) claimed to have less than one partner per week, 85% (85/100) only one partner per week, 5% (5/100) two to three partners per week, 2% (2/100) more than three partners per week, and 2% (2/100) did not respond. This information is reinforced by our results, as 92% (92/100) of the subjects claimed to have only one partner per week when it comes to kissing the lips of another person. It is known that multiple contacts on one same day is rather common among young people in our society (thus the question was included in the questionnaire). Additionally, we must consider the relevance of the reported use of condoms; 46% (46/100) claimed they always use it, 26% (26/100) use it sometimes. The few individuals - 3% (3/100) - who reported to have sex with three partners per week and claimed not to wear condoms 1% (1/100) or to wear them sometimes - 2% (2/100), also had negative test results for HPV. The predominantly monogamist behavior and of using condoms by the subjects in our sample may have contributed for the absence of HPV positive test results.

Impact of tobacco and alcohol: differently from what was observed in genital cancer, the impact of smoking in the progress of high-risk HPV infection and oral and
oropharyngeal cancer is more controversial, sometimes dissociating such factors, at times seeing increases and even decreases in tumor prevalence rates. Although some reports indicate that tobacco and alcohol may be risk factors for oral and oropharyngeal carcinoma, increased incidence of SCC in populations where tobacco and alcohol consumption were reduced for some time indicates other risk factors might be at play. Reinforcing this idea, authors reported on male patients with oral and oropharyngeal SCC in which the group of heavy smokers had lower rates of infection by HPV. There seems to be a preventive effect of tobacco in oral and oropharyngeal infection by HPV, resulting probably from increases in keratinization of mucosal surfaces, rendering them stronger against minor trauma and less susceptible to HPV basal layer cell infection. Only 3% (3/100) of the subjects in our sample claimed to be smokers, a fact that certainly did not impact the results reported.

For alcohol consumption, 32% (32/100) of the subjects claimed they did not drink, 55% (55/100) said they had it once a week, 3% (3/100) had it twice a week, 6% (6/100) had it three times a week, and 4% (4/100) did not respond. Alcohol consumption was therefore reduced and of little significance. High alcohol consumption patterns seem to work synergistically with high risk HPV infection, a factor not applicable to the studied sample.

Therefore, the impact of tobacco and alcohol consumption upon oral mucosa HPV infection should be further clarified.

Persistence of HPV infection and immune aspects: infection by HPV takes place at the beginning of sex life, somewhere between adolescence and early twenties. In most of the cases the infection is transient, and no clinical evidence indicates whether the disease can be suppressed or eliminated at all, unless immune incompetence sets in. Some persistent infections by high-risk virus types may evolve to genital cancer. Most of the time, the disease is diagnosed between the ages of 25 and 29 years. There are evidences that HPV infection is a transient or intermittent phenomenon, with an average duration of 12 months. There seems to be a difference in viral biologic activity between men and women, as male subjects tend to have more of a fluctuating infection with periods of spontaneous remission possibly due to their immune status, local factors, and the various forms of organization of the genital epithelium in both genders. Our study looked into a narrowly aged population (mean age = 22.65 years) of both genders (60 females and 40 males), and samples may have been collected during a healing period.

Impact of diagnostic tool limitation: there still is variation in detection rates, depending on the chosen mucosal sample collection method, namely scrapes, lavages, or biopsy and the elected PCR assay. Although scrapes were used and samples were kept refrigerated so as to allow for better detection of HPV DNA, this method extracts only superficial epithelial cells that are infected in subclinical and clinical infection. Therefore, no viruses from latent infections in the basal or suprabasal layer cells are removed. Primers MY09 and MY11 and GP5+/GP6+ were used in our study, as they are the most routinely used in HPV DNA detection and are able to identify a wide range of different viruses in one single reaction. Reports indicate differences in the results obtained with different primers for one same sample, meaning different primers amplify different HPV genotypes. Detection of mixed infections can only be done by using various primer pairs in the PCR test. Considering this limitation, not using various primer pairs in our study would increase the number of false negative test results. The wide variation in prevalence rates observed in various papers may be partially explained by the difference found in biopsies of normal patients and subjects with lesions in different tests (SB and PCR). Different tests done on one same group of samples could add consistency to comparative analyses. Another similar study, however enrolling fewer subjects, found positive HPV PCR tests in three patients, while the SB of these same patients was negative for HPV. This reinforces the fact that results will depend on the sensitivity of each test.

The existence of local factors, as well as the fact that saliva has components that may have a protective effect such as lysozymes, lactoferrin, IgA, and cytokines could explain the low transmission rates through self-inoculation and oral sex.

Although the fact that virus prevalence rates range between 0% and 100% in normal individuals indicates the possibility that the oral mucosa may work as a reservoir of viruses, HPV may be considered as a risk factor for oral cancer. Immune disorders could impact HPV infection towards latency, cure, or carcinogenesis. HPV types 16 and 18 are strongly associated with early proteins (E6 and E7) which inhibit tumor suppressing genes (p53 and pRB) and 18 - associated with early proteins (E6 and E7) which inhibit tumor suppressing genes (p53 and pRB) and induce increased rates of mitosis, thus enhancing the possibility of viral DNA being integrated to cell DNA. Integrated HPV DNA found in SCC genome points to the thesis that this virus could be an important factor in the etiology of some head and neck carcinomas.

CONCLUSION

No traces of HPV were found in our sample based on the tests performed in our study. The vast variation (0-100%) on HPV prevalence rates found in the oral mucosa of healthy individuals found in the literature may indicate that the methods used to detect the virus need to be reassessed. It is our belief that more studies should be conducted to assist in the development of new methods that introduce new elements to clarify how HPV behaves in oral mucosa infection.
REFERENCES

1. Oliveira MC, Soares RC, Pinto LP, Costa ALL. HPV e carcinogênese oral: revisão bibliográfica. Rev Bras Otorrinolaringol. 2003;69:553-9.
2. Castro TMPPG, Bussoloti Filho I, Prevalência do papilomavirus humano (HPV) na cavidade oral e na orofaringe. Braz J Otorhinolaringol. 2006;7:272-82.
3. Collier B, Goodbar-Larson L, Sokolowski, Schwartz S. Translation. Inhibition in Vitro of Human Papillomavirus Type 16 L2 mRNA Mediated trough Interaction with Heterogenous Ribonucleoprotein K and Poly (oc) binding Proteins 1 and 2. J Biol Chem. 1998; 273:22648-56.
4. Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, BrownJC. Southern blot hybridization and PCR in detection of oral human papillomavirus infections in adults and children. J Infect Dis. 1990;162:60-9.
5. Summersgill KF, Smith EM, Levy BT, Allen JM, Haugen TH, Turek LP. Human papillomavirus: disease and laboratory diagnosis. Br J Biomed Sci. 1997;54:299-303.
6. Sinogas C, Rodrigues A, Reis D. Papilomavirus Humano Biologia e Epidemiologia. Universidade de Évora, Departamento de Biologia. http://evunix.uevora.pt/~sinogas/TRABALHOS/2004/papiloma.htm
7. Castro TMPPG. A frequência de papilomavírus humano (HPV) na mucosa oral de mulheres portadoras de HPV genital confirmado pela PCR. Tese (Doutorado). São Paulo. Faculdade de Ciências Médicas da Santa Casa de São Paulo; 2007.
8. Garlick JA, Taichman LB. Human papillomavirus infection of the oral mucosa. Am J Dermatopathol. 1991;3:386-95.
9. Summerrigl KF, Smith EM, Levy BT, Allen JM, Haugen TH, Turek LP. Human papillomavirus in the oral cavities of children and adolescents. Oral Surg Oral Med Oral Pathol. 2001;91:62-9.
10. Hou SY, Wu SY, Chieng C. Transcriptional activity among high and low risk human papillomavirus E2 proteins correlates with DNA binding. J Biol Chem. 2002;277:45619-29.
11. Tinoco JA, Silva AF, Oliveira CAB, Rapoport A, Fava AS, Souza RP. Correlação da infecção viral pelo papilomavirus humano com as lesões papilomatosas e o carcinoma epidermoide na boca e orofaringe. Rev Assoc Med Bras. 2004;50:252-6.
12. Ozbun MA. Infectious human papillomavirus type 31b: purification and infection of an immortalized human keratinocyte cell line. J Gen Virol. 2002;83:2753-63.
13. Xavier SD, 2007, Frequência de aparecimento do papilomavirus humano (HPV) na mucosa oral de homens com HPV genital confirmado por biologia molecular. Tese (Mestrado). São Paulo; 2007.
14. Zur Hausen, de Villiers EM, Human Papillomaviruses. Annu Rev Microbiol. 1994;48:427-47.
15. Gutman LT, Herrman-Giddens ME, Phelps WC. Transmission of human genital papillomavirus disease: comparison of data from adults and children. Pediatrics. 1993;91:31-8.
16. Cason J, Kaye JN, Jewers RJ, Kambo PK, Bible JM, Kell B et al. Perinatal infection and persistence of human papillomavirus types 16 and 18 in infants. J Med Virol. 1995;47:209-18.
17. Tominaga S, Fukushima K, Nishizaki K, Watanabe S, Masuda Y, Ogura H. Presence of human papillomavirus type 6f in tonsilar condiloma acuminatum and clinically normal tonsillar mucosa, Jpn J Clin Oncol. 1996;26:393-6.
18. Okada MMK, Gonçalves MAG, Giraldo PC. Epidemiologia e patogênese do papilomavirus humano (HPV): In: 1º Consenso Brasileiro de HPV. 2000. 1ª edição: São Paulo; Editora BG. 2000:01-6.
19. Kellokoski JK, Sirjänen SM, Chang F, Yliskoski M, Syrjänen KJ. Structures of bovine and human papillomaviruses. Biophys J. 1991;60:717-33.
20. Soares CR, Malavasi I, Reis RI, Neves, KA, Zuanon JAS, Benatti Neto C, Spolidório LC, Oliveira MRB. Presença de papilomavírus humano (HPV) na mucosa oral de homens com HPV genital confirmado. Rev Soc Bras de Med Trop. 2002;15:401-5.
21. Dhahlstrom KR, Adler-Storthz K, Etzel CJ, Liu Z, Dilllon L, El-Naggar AK, Spits MR, et al. Human Papillomavirus Type 16 Infection and Squamous Cell Carcinoma of the Head and Neck in Never-Smokers. Clin Cancer Res. 2003;9:2620-6.
43. Syrjänen S. HPV infections and tonsillar carcinoma. J Clin Pathol. 2004;57:449-55.
44. Ritchie JM, Smith EM, Summersgill KF, Hoffman HT, Wang D, Klussmann JP et al. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer. 2003;104:336-44.
45. Russomano F, 2000. Presença de HPV nos fluidos em geral. Available from: URL: http://www.cervical.com.br.
46. Ha PK, Califano JA. The role of human papillomavirus in oral carcinogenesis. Crit Rev Oral Biol Med. 2004;15:188-96.
47. Hoffmann M, Khan T, Mahnke CG, Goeroge T, Lippert BM, Werner JA. Prevalence of human papillomavirus in squamous cell carcinoma of the head and neck determined by polymerase chain reaction and southern blot hybridization: proposal for optimized diagnostic requirements. Acta Otolaryngol (Stockh). 1998; 118:138-44.
48. Melo A, Roa I, Montenegro S, Capurro I, Roa JC. Estudio comparativo de detección del virus papiloma humano (VPH) en muestras citológicas y biopsias de cuello uterino. Rev Med Chil. 2005;133:639-44.
49. Ribeiro KMX. Estudo da ocorrência do papilomavírus humano em tonsilas palatinas na população pediátrica. Tese (Mestrado) São Paulo; 2002.
50. Kado S, Kawamata Y, Shino Y, Kasai T, Kubota K, Iwasaki H et al. Detection of human papillomavirus in cervical neoplasias using multiple sets of generic polymerase chain reaction primers. Gynecol Oncol. 2001;81:47-52.